

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/

<b>Name of entity</b>	Noxopharm Limited (ASX: NOX)
<b>ABN</b>	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Frederik Bart
<b>Date of last notice</b>	29 June 2020

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	22 - 24 July 2020
<b>No. of securities held prior to change</b>	<u>DIRECT</u> <ul style="list-style-type: none"><li>5,594,780 ordinary shares</li><li>1,864,927 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30</li></ul>
<b>Class</b>	1. Ordinary shares 2. Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30
<b>Number acquired</b>	N/A
<b>Number disposed</b>	<u>DIRECT</u> <ul style="list-style-type: none"><li>(3,056,318) ordinary shares</li><li>(1,018,773) Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30</li></ul>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	1. Average of \$0.3439 per ordinary share – total of consideration paid is \$1,051,211.84 (\$1,039,606.81 after brokerage) 2. Average of \$0.1915 per Listed Option – total of consideration paid is \$195,051.68 (\$192,917.79 after brokerage)  Profit on sale (after brokerage) to be donated to Charity
<b>No. of securities held after change</b>	<u>DIRECT</u> 1. 2,538,462 ordinary shares 2. 846,154 Listed Options Expiry, 18/06/2023, Exercisable @ \$0.30
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market transfer further to Notice of Contravention of Listing Rule 10.11

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Yes, however sale was required within that period pursuant to requirements of ASX (see announcement re Notice of Contravention of Listing Rule 10.11)
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes
<b>If prior written clearance was provided, on what date was this provided?</b>	21 July 2020 (effective from)

---

<sup>+</sup> See chapter 19 for defined terms.